Telix Pharmaceuticals (Australia) Performance
| TLX Stock | 24.74 0.96 4.04% |
On a scale of 0 to 100, Telix Pharmaceuticals holds a performance score of 16. The entity has a beta of 0.56, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Telix Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Telix Pharmaceuticals is expected to be smaller as well. Please check Telix Pharmaceuticals' value at risk, expected short fall, and the relationship between the treynor ratio and downside variance , to make a quick decision on whether Telix Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
16 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Telix Pharmaceuticals are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Telix Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Telix expansion spree rolls on with 250M acquisition of RLS Radiopharmacies - FiercePharma | 09/23/2024 |
2 | Telix Pharmaceuticals Strong Momentum Presents Opportunity - Seeking Alpha | 10/30/2024 |
| Begin Period Cash Flow | 116.3 M |
Telix |
Telix Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,801 in Telix Pharmaceuticals on September 1, 2024 and sell it today you would earn a total of 673.00 from holding Telix Pharmaceuticals or generate 37.37% return on investment over 90 days. Telix Pharmaceuticals is generating 0.5123% of daily returns assuming 2.4777% volatility of returns over the 90 days investment horizon. Simply put, 22% of all stocks have less volatile historical return distribution than Telix Pharmaceuticals, and 90% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Telix Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Telix Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Telix Pharmaceuticals, and traders can use it to determine the average amount a Telix Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2068
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TLX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.48 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.51 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.21 actual daily | 16 84% of assets perform better |
Based on monthly moving average Telix Pharmaceuticals is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Telix Pharmaceuticals by adding it to a well-diversified portfolio.
Telix Pharmaceuticals Fundamentals Growth
Telix Stock prices reflect investors' perceptions of the future prospects and financial health of Telix Pharmaceuticals, and Telix Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Telix Stock performance.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0797 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 8.18 B | ||||
| Shares Outstanding | 334.72 M | ||||
| Price To Book | 20.50 X | ||||
| Price To Sales | 12.83 X | ||||
| Revenue | 496.66 M | ||||
| Gross Profit | 98.54 M | ||||
| EBITDA | 22.97 M | ||||
| Net Income | 5.21 M | ||||
| Total Debt | 17.45 M | ||||
| Book Value Per Share | 1.21 X | ||||
| Cash Flow From Operations | 23.88 M | ||||
| Earnings Per Share | 0.15 X | ||||
| Total Asset | 398.3 M | ||||
| Retained Earnings | (263.67 M) | ||||
About Telix Pharmaceuticals Performance
Assessing Telix Pharmaceuticals' fundamental ratios provides investors with valuable insights into Telix Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Telix Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Telix Pharmaceuticals is entity of Australia. It is traded as Stock on AU exchange.Things to note about Telix Pharmaceuticals performance evaluation
Checking the ongoing alerts about Telix Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Telix Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Telix Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| About 41.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Telix Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Telix Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Telix Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Telix Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Telix Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Telix Pharmaceuticals' stock. These opinions can provide insight into Telix Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.